Holen Sie sich die Stockscreener-App
0.624
4.00%
-0.026
Vorhandelsmarkt:
.63
0.006
+0.96%
Schlusskurs vom Vortag:
$0.65
Offen:
$0.65
24-Stunden-Volumen:
172.59K
Relative Volume:
0.35
Marktkapitalisierung:
$2.71M
Einnahmen:
$7,500
Nettoeinkommen (Verlust:
$-9.84M
KGV:
-0.109
EPS:
-5.7263
Netto-Cashflow:
$-9.25M
1W Leistung:
-20.81%
1M Leistung:
-21.21%
6M Leistung:
-51.25%
1J Leistung:
-91.74%
1-Tages-Spanne:
$0.611
$0.6796
1-Wochen-Bereich:
$0.611
$0.7998
52-Wochen-Spanne:
$0.611
$9.60
Oragenics Inc Stock (OGEN) Company Profile
Firmenname
Oragenics Inc
Sektor
Branche
Telefon
813-286-7900
Adresse
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.624 | 2.82M | 7,500 | -9.84M | -9.25M | -5.7263 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Oragenics Inc Aktie (OGEN) Neueste Nachrichten
Oragenics (OGEN) Reports Going Concern Risk in Latest Audit - GuruFocus
OGEN SEC FilingsOragenics 10-K, 10-Q, 8-K Forms - Stock Titan
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - GlobeNewswire
Volume Recap: Is Oragenics Inc vulnerable to short sellers2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
If You Invested $1,000 in Oragenics (OGEN) - Stock Titan
[EFFECT] ORAGENICS INC SEC Filing - Stock Titan
Growth Report: Is Oragenics Inc forming bullish engulfing patterns2026 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
OGEN Forecast, Price Target & Analyst Ratings | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics (NASDAQ: OGEN) updates S-3/A with auditor consent - Stock Titan
Oragenics Files 2025 Annual Report, Highlights Progress in Concussion Treatment Development - citybuzz -
Oragenics Submits Annual Report Highlighting Fiscal Year 2025 Financials and Research Updates - geneonline.com
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K - The Manila Times
Biotech Oragenics raises $16.5M, clears debt to fund concussion drug trial - Stock Titan
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Oragenics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION - Sahm
Oragenics Initiates First Clinical Site for Phase IIa Trial of Intranasal Concussion Treatment - citybuzz -
Oragenics Inc Initiates Phase Iia Clinical Trial Site Activation - marketscreener.com
Oragenics (OGEN) Advances Phase IIa Clinical Trial of ONP-002 in Australia - GuruFocus
Oragenics begins testing nasal concussion treatment in Australia - Stock Titan
Oragenics Receives Australian HREC Approval to Begin Phase IIa Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury - Minichart
Oragenics Advances Concussion Drug Trial and Explores CNS Asset Acquisitions - TipRanks
Oragenics Explores CNS Asset Acquisitions to Expand Brain Health Pipeline - citybuzz -
Oragenics (OGEN) Eyes Expansion in Central Nervous System Sector - GuruFocus
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION - The Manila Times
Oragenics (OGEN) Receives Approval for Phase IIa Concussion Drug Trial in Australia - GuruFocus
Oragenics Receives HREC Approval for Phase IIa Clinical - GlobeNewswire
Is Oragenics Inc forming bullish engulfing patterns2025 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Inflation Data: Is Oragenics Inc a strong candidate for buy and holdJuly 2025 Sentiment & High Return Trade Guides - baoquankhu1.vn
Aug Technicals: What is the target price for Oragenics Inc stockPortfolio Performance Report & Momentum Based Trading Signals - baoquankhu1.vn
OGEN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Momentum Shift: Is Oragenics Inc vulnerable to short sellersJuly 2025 Update & Weekly Breakout Stock Alerts - baoquankhu1.vn
How Oragenics Inc. stock trades pre earningsJuly 2025 Pullbacks & Risk Managed Investment Entry Signals - mfd.ru
OGEN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can Oragenics Inc. sustain its profitabilityJuly 2025 Macro Moves & Consistent Return Investment Signals - mfd.ru
Is Oragenics Inc. vulnerable to short sellers2025 Key Lessons & Verified Chart Pattern Signals - mfd.ru
Oragenics previews targeted milestones for 2026 - Yahoo Finance
Oragenics (OGEN) Progresses ONP-002 for Potential $9 Billion Con - GuruFocus
Oragenics Targets Projected $9 Billion Market by Advancing - GlobeNewswire
Portfolio Shifts: What is the next catalyst for Oragenics IncJuly 2025 Closing Moves & Consistent Return Investment Signals - baoquankhu1.vn
Oragenics partners with Duck Flats Pharma to support FDA IND trial design - Yahoo Finance
Oragenics (OGEN) Partners with Duck Flats Pharma for U.S. IND Re - GuruFocus
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program - Sahm
Oragenics Advances Concussion Treatment Development with SCOPE Summit Participation Ahead of Australian Phase 2a Trial - citybuzz -
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care - GlobeNewswire
Investor Mood: Is Oragenics Inc stock technically oversold2025 Risk Factors & Growth Focused Stock Reports - baoquankhu1.vn
Market Trends: Is now the right time to enter LPLAWeekly Trade Summary & Reliable Breakout Forecasts - baoquankhu1.vn
Rate Hike: What is the next catalyst for Oragenics IncQuarterly Portfolio Summary & Verified Entry Point Detection - baoquankhu1.vn
Oragenics Extends At-the-Market Equity Sales Agreement - The Globe and Mail
Oragenics amends at-the-market sales agreement with Dawson James Securities By Investing.com - Investing.com Australia
Oragenics amends at-the-market sales agreement with Dawson James Securities - Investing.com
Finanzdaten der Oragenics Inc-Aktie (OGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):